Acreage Holdings Past Earnings Performance
Past criteria checks 0/6
Acreage Holdings has been growing earnings at an average annual rate of 12.2%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 28.3% per year.
Key information
12.2%
Earnings growth rate
18.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 28.3% |
| Return on equity | n/a |
| Net Margin | -38.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Acreage Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 213 | -82 | 83 | 0 |
| 31 Dec 23 | 223 | -69 | 87 | 0 |
| 30 Sep 23 | 228 | -133 | 96 | 0 |
| 30 Jun 23 | 233 | -148 | 102 | 0 |
| 31 Mar 23 | 236 | -142 | 105 | 0 |
| 31 Dec 22 | 237 | -140 | 107 | 0 |
| 30 Sep 22 | 238 | -85 | 106 | 0 |
| 30 Jun 22 | 224 | -75 | 101 | 0 |
| 31 Mar 22 | 207 | -68 | 101 | 0 |
| 31 Dec 21 | 189 | -63 | 99 | 0 |
| 30 Sep 21 | 162 | -60 | 122 | 0 |
| 30 Jun 21 | 146 | -88 | 131 | 0 |
| 31 Mar 21 | 129 | -122 | 148 | 0 |
| 31 Dec 20 | 115 | -287 | 186 | 0 |
| 30 Sep 20 | 104 | -300 | 197 | 0 |
| 30 Jun 20 | 95 | -298 | 218 | 0 |
| 31 Mar 20 | 85 | -299 | 228 | 0 |
| 31 Dec 19 | 74 | -150 | 201 | 0 |
| 30 Sep 19 | 63 | -125 | 163 | 0 |
| 30 Jun 19 | 47 | -99 | 124 | 0 |
| 31 Mar 19 | 32 | -47 | 78 | 0 |
| 31 Dec 18 | 21 | -27 | 47 | 0 |
| 30 Sep 18 | 13 | -8 | 31 | 0 |
| 30 Jun 18 | 9 | 3 | 17 | 0 |
| 31 Mar 18 | 8 | -11 | 13 | 0 |
| 31 Dec 17 | 8 | -9 | 10 | 0 |
| 31 Dec 16 | 4 | -2 | 3 | 0 |
Quality Earnings: 0VZ1 is currently unprofitable.
Growing Profit Margin: 0VZ1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0VZ1 is unprofitable, but has reduced losses over the past 5 years at a rate of 12.2% per year.
Accelerating Growth: Unable to compare 0VZ1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0VZ1 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.2%).
Return on Equity
High ROE: 0VZ1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.